Our team was able to develop the first human microbiome reference ranges by working with data from healthy individuals selected from the largest microbiome dataset in the world.
San Francisco, CA (PRWEB)
May 04, 2017
uBiome, the microbial genomics leader, has today published detailed descriptions of a novel approach to testing for gut health. This paper, authored by a team of scientists at uBiome, appears in the leading open access peer-reviewed scientific journal PLOS ONE. For the first time, this new methodology enables comparison of levels of specific microorganisms with reference ranges obtained from healthy individuals.
A number of conditions are associated with changes in the relative abundances of microorganisms in the gut. uBiome’s method gives healthcare providers access to a reporting system that is able to identify and quantify intestinal microbes, comparing them with a healthy reference range. uBiome’s diagnostic tool reports on 28 clinically relevant taxa, including both pathogenic, beneficial, and commensal bacteria. A more advanced version of this technology is used in the company’s SmartGut™ test for doctors to prescribe to their patients. SmartGut is a lab-developed test processed in uBiome’s CLIA-certified and CAP-accredited laboratory in San Francisco.
The process reported in the PLOS ONE article identifies 28 clinical prokaryotic targets including 14 species and 14 genera, representing 20 commensals, three probiotics (beneficial microorganisms), and five pathogenic taxa, including C. difficile and Salmonella enterica. uBiome’s approach uses next generation DNA sequencing, which enables the calculation of abundance of bacteria and the automatic calculation of healthy ranges. uBiome’s vast data set has allowed the development of reference…